Transgenomic to Raise $22M in Private Placement | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Transgenomic announced today it has entered into definitive agreements to raise about $22 million in a private placement.

The deal is with institutional and other accredited investors and as part of it, the Omaha, Neb.-based firm will issue an aggregate of 19 million shares of its stock at $1 per share and five-year warrants to purchase up to an aggregate of 9.5 million shares of Transgenomic stock at an exercise price of $1.25 per share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: role for epigenetic in neuronal excitability, and more.

The new Office of Research Integrity director is grappling with complaints from her staff, according to ScienceInsider.

Italian researchers link SNPs in the PDSS2 gene to coffee consumption in a new paper.

A gene-editing ban has been interpreted to include mitochondrial transfer, Technology Review reports.